Grant: Knowledge Synthesis Grant: Socio-Economic Burden of Inherited Disease
University of Calgary
$99,545.00
Let's Start Counting (and make it count)! A scoping review of the socioeconomic burden of rare genetic diseases
EF 2019-20
Résumé
There are more than 5600 single-gene disorders (diseases primary caused by one gene), and while they are individually rare, when considered as a group these diseases contribute significantly to illness, death, quality of life and healthcare costs. Rare genetic diseases affect both children and adults. They can impact schooling, job possibilities, and family life. In addition to the emotional burden, the cost of obtaining a diagnosis for a rare genetic disease may reach more than US$10,000 per person. Treatments may not be available, and when they are they can be very expensive.
Previous estimates of the cost of caring for individuals with rare genetic diseases vary and do not capture the full socioeconomic burden (SEB) of these diseases. SEB can include four key cost areas: costs to the health care system (for example, specialist visits, tests and procedures); costs to other government sectors (for example, home care); costs to patients and families (for example, travel, mobility aids); and costs to individuals and society associated with work impacts (for example, time off work due to poor health or inability to work at all).
We aim to identify the specific elements that should be measured within each cost area. We will review the studies in the literature on SEB of rare genetic diseases to see how well they capture the elements we identified. We will then describe what is missing, and provide suggestions for ways to do better studies in the future. This will allow future studies to produce clear and comparable estimates of the costs of individual diseases. In turn, this will mean we can add them together to understand the burden of these rare genetic diseases as a whole. This will help governments to make sure that fair decisions are being made about how to use Canada's scarce health care funds.
Programme
Knowledge Synthesis Grant: Socio-Economic Burden of Inherited Disease
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
411615
Name
Marshall Deborah A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Health systems / services
Prcname2
Knowledge Synthesis Grant: Socio-Economic Burden of Inherited Disease
Projecttitle
Let's Start Counting (and make it count)! A scoping review of the socioeconomic burden of rare genetic diseases
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$99,545
Cihrequipment2
$0
Programname2
Knowledge Synthesis Grant: Socio-Economic Burden of Inherited Disease
Keyworddelim
Burden Of Illness; Rare Genetic Disease; Scoping Review; Socioeconomic Costs
Abstract
There are more than 5600 single-gene disorders (diseases primary caused by one gene), and while they are individually rare, when considered as a group these diseases contribute significantly to illness, death, quality of life and healthcare costs. Rare genetic diseases affect both children and adults. They can impact schooling, job possibilities, and family life. In addition to the emotional burden, the cost of obtaining a diagnosis for a rare genetic disease may reach more than US$10,000 per person. Treatments may not be available, and when they are they can be very expensive.
Previous estimates of the cost of caring for individuals with rare genetic diseases vary and do not capture the full socioeconomic burden (SEB) of these diseases. SEB can include four key cost areas: costs to the health care system (for example, specialist visits, tests and procedures); costs to other government sectors (for example, home care); costs to patients and families (for example, travel, mobility aids); and costs to individuals and society associated with work impacts (for example, time off work due to poor health or inability to work at all).
We aim to identify the specific elements that should be measured within each cost area. We will review the studies in the literature on SEB of rare genetic diseases to see how well they capture the elements we identified. We will then describe what is missing, and provide suggestions for ways to do better studies in the future. This will allow future studies to produce clear and comparable estimates of the costs of individual diseases. In turn, this will mean we can add them together to understand the burden of these rare genetic diseases as a whole. This will help governments to make sure that fair decisions are being made about how to use Canada's scarce health care funds.
Competitiondate
201909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Marshall, Deborah A; Lorenzetti, Diane
Approvedterm
1 an 0 mois
Cihrcontribution2
Institute of Genetics~ $99,545~ $0~